Fortitude Biomedicines raises $13m seed round
K2 Bio Partners, Shanghai Healthcare Angel Capital and other backers participated in the financing.
Fortitude Biomedicines raised $13 million in seed financing on January 26. Participants included K2 Bio Partners, Shanghai Healthcare Angel Capital, Elikon Venture, Everjoy Fortune and Taihill Venture. The company develops antibody-based therapies for autoimmune diseases and cancer.